[ad_1]
This article is over a month old and may contain outdated advice from authorities on coronary heart disease.
Stay up to date on the NRK overview or on the FHI website.
British health authorities announced it today.
The vaccine is being developed by Pfizer / BioNtech and UK authorities are now working to make a list of who should be prioritized.
– We are ready to start vaccination next week, but it will be a difficult priority as the quantity is limited, says British Health Minister Matt Hancock, who further says they are now in the process of building large vaccine centers in various locations from the country. .
Right now, 50 hospitals are preparing to start vaccinating.
Biontech, Fosun Pharma and Pfizer
The German pharmaceutical company BioNTech reports that their coronary vaccine has been shown to be 95 percent effective. The UK will start vaccinating in December.
The BNT162b2 vaccine relies on your body’s system for building things. The vaccine is just building instructions for the cells. The instructions are based on the same codes that cells use all the time for this purpose. These are called mRNA or “messenger ribonucleic acid.”
What happens is the following:
The vaccine is injected into your body. The information from the vaccine reaches the machines in the cells that make proteins. These machines build copies of the so-called “spike protein” of the coronavirus. These proteins are secreted by cells and detected by the immune system. The immune system reacts in the same way as if the real coronavirus had entered the body. Antibodies are produced and the immune system remembers that the coronavirus is something else to react to.
You have been vaccinated.
– Good sign
– What we know is that the English government adopted rules that led to the pharmaceutical authorities to give an emergency approval to this vaccine, says Steinar Madsen, medical director of the Norwegian Medicines Agency of NRK.
– What does this mean for the start of vaccination?
– It is said that they will be able to start the vaccination next week, but we will have to wait to see if this will be the case.
– What will this mean for the vaccine for the rest of the world?
– That’s a good sign. This is the first approval, so one could expect an approval in the US in the middle of the month and an approval for all of Europe in late December. I don’t think this has any direct meaning, but of course it is very interesting that the British have acted so quickly, says Madsen.
Pfizer claims that they will start shipping vaccine doses to the UK immediately and are ready to do the same in the US if the FDA approves the vaccine there.
– It’s a historic moment. We are focused on being able to quickly supply a vaccine that maintains high quality around the world, says Pfizer CEO Albert Bourla.
The UK has ordered doses for 20 million people, but it is unclear how many of them will arrive during December. Also, Pfizer vaccine must be stored at very cold temperatures.
First in the world
Pfizer / BioNtech and Moderna were the first two to report that their vaccines had a good effect, and they were also the first to ask the EU to approve the products.
The European Medicines Agency (EMA) is scheduled to process the Pfizer / BioNtech vaccine on December 29, while the Moderna vaccine will be discussed on January 12.
The vaccine for Pfizer / BioNtech has now been approved by the UK.
– This is a conditional approval, which means an approval based on available data. Then more data will be collected over time. The British have probably chosen an even faster way that can be called a kind of urgent approval, says Madsen.
If the vaccines are approved for temporary use in Europe, the question is how quickly Norway can get vaccines and who should get vaccinated.
– When do you think we will be able to start vaccinating people in Norway?
– It will probably be during the New Year, because the plan in Europe is to have a meeting on December 29, where the European Scientific Committee will present a recommendation on the approval of this BioNTech-Pfizer vaccine.
Madsen has previously stated that the work to develop a coronary vaccine has been unusually fast. At the same time, security appears to be well cared for, including through extensive reviews of preliminary test results.
Health workers first
The Pfizer vaccine is given in two doses three weeks apart. The UK will prioritize healthcare workers and nursing home residents, then the elderly.
The British Medicines Agency is also considering another vaccine, produced by AstraZeneca and the University of Oxford. However, Prime Minister Boris Johnson warned that a harsh winter with a series of restrictions must first be overcome, to limit the spread of the coronavirus until there are enough vaccines for all who need it.
